Shine Medical Tech Breaks Ground On Isotope Production Plant

Wisconsin-based SHINE Medical Technologies, Inc., announced May 9 that the company had launched into construction of their first medical isotope production facility in Janesville, Wisconsin with a ground-breaking ceremony.

Shine Medical Technologies groundbreaking ceremonyUS Department of Energy (DOE) Under Secretary for Nuclear Security and Administrator of the National Nuclear Security Administration (NNSA) Lisa Gordon-Hagerty, Lantheus Medical Imaging President and CEO Mary Heino and Janesville City Manager Mark Freitag joined SHINE founder and CEO, Greg Piefer, were in attendance to celebrate the milestone, the company announced.

“Construction of the Janesville production facility is a critical step toward establishing a reliable global supply of life-saving diagnostic and therapeutic isotopes for patients around the world,” said Greg Piefer, SHINE founder and CEO. “We are excited and confident as we move into the execution phase of our plans to become the global leader in the production of medical isotopes," he said.

Once complete, the 43,000 square foot facility to be located across from the Southern Wisconsin Regional Airport, will be home to eight of SHINE’s accelerator-based medical isotope production systems, capable of producing over one-third of global demand for the life-saving medical isotope, molybdenum-99 (Mo-99).

SHINE currently employs over 90 people and expects to hire approximately 60 more before the completion of the facility.

Shine was founded in 2010 as a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The company uses a proprietary manufacturing process that does not require a nuclear reactor and is said to generate less waste than traditional techniques. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging.

In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. 

Anonymous comments will be moderated. Join for free and post now!